LIVIVO - Search results -

Search results

Result 1 - 10 of total 47

Search options

Article ; Online: Isavuconazole as an alternative for antifungal prophylaxis in patients with hematological malignancies: Is the signal sufficient to support clinical practice?

Villalobos, Armelle Perez-Cortes / Bow, Eric J

Transplant infectious disease : an official journal of the Transplantation Society

2023 Volume 25, Issue 2, Page(s) e14046

MeSH term(s)	Humans ; Antifungal Agents/therapeutic use ; Triazoles/therapeutic use ; Nitriles/therapeutic use ; Hematologic Neoplasms/complications
Chemical Substances	Antifungal Agents ; isavuconazole (60UTO373KE) ; Triazoles ; Nitriles
Language	English
Publishing date	2023-03-02
Publishing country	Denmark
Document type	Editorial
ZDB-ID	1476094-0
ISSN	1399-3062 ; 1398-2273
ISSN (online)	1399-3062
ISSN	1398-2273
DOI	10.1111/tid.14046
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5100: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections.

Cuvelier, Geoffrey D E / Paulson, Kristjan / Bow, Eric J

Transplant infectious disease : an official journal of the Transplantation Society

2023 Volume 25 Suppl 1, Page(s) e14101

Abstract: Background: Infectious disease physicians may be asked to evaluate and manage a variety of infections in immunocompromised hosts undergoing hematopoietic cell transplant (HCT) and cellular therapies. Over the last decade, several advances in cellular ... ...

Abstract	Background: Infectious disease physicians may be asked to evaluate and manage a variety of infections in immunocompromised hosts undergoing hematopoietic cell transplant (HCT) and cellular therapies. Over the last decade, several advances in cellular therapy have occurred, with implications for the types of infectious complications that may be seen. Aims: The purpose of this review is to update the infectious disease physician on newer advances in HCT and cellular therapy, including haploidentical transplant, expanding indications for transplant in older individuals and children, and chimeric antigen receptor T-cells. We will review how these advances might influence infectious disease complications following HCT. We will also provide a perspective that infectious disease physicians can use to evaluate the degree of immune suppression in an individual patient to help determine the type of infections that may be encountered.
MeSH term(s)	Child ; Humans ; Aged ; Hematopoietic Stem Cell Transplantation/adverse effects ; Transplantation, Homologous ; Immunosuppression Therapy ; Opportunistic Infections ; Communicable Diseases
Language	English
Publishing date	2023-07-18
Publishing country	Denmark
Document type	Journal Article ; Review
ZDB-ID	1476094-0
ISSN	1399-3062 ; 1398-2273
ISSN (online)	1399-3062
ISSN	1398-2273
DOI	10.1111/tid.14101
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5100: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Low-Efficacy Mu Opioid Agonists as Candidate Analgesics:

Santos, Edna J / Akbarali, Hamid I / Bow, Eric W / Chambers, Dana R / Gutman, Eugene S / Jacobson, Arthur E / Kang, Minho / Lee, Young K / Lutz, Joshua A / Rice, Kenner C / Sulima, Agnieszka / Negus, S Stevens

The Journal of pharmacology and experimental therapeutics

2024

Abstract: Low efficacy mu opioid receptor (MOR) agonists may serve as novel candidate analgesics with improved safety relative to high-efficacy opioids. This study used a recently validated assay of pain-depressed behavior in mice to evaluate a novel series of MOR- ...

Abstract	Low efficacy mu opioid receptor (MOR) agonists may serve as novel candidate analgesics with improved safety relative to high-efficacy opioids. This study used a recently validated assay of pain-depressed behavior in mice to evaluate a novel series of MOR-selective C9-substituted phenylmorphan opioids with graded MOR efficacies. Intraperitoneal injection of dilute lactic acid (IP acid) served as a noxious stimulus to depress locomotor activity by mice in an activity chamber composed of two compartments connected by an obstructed door. Behavioral measures included (1) crosses between compartments (vertical activity over the obstruction) and (2) movement counts quantified as photobeam breaks summed across compartments (horizontal activity). Each drug was tested alone and as a pretreatment to IP acid. A charcoal-meal test and whole-body-plethysmography assessment of breathing in 5% CO
Language	English
Publishing date	2024-04-18
Publishing country	United States
Document type	Journal Article
ZDB-ID	3106-9
ISSN	1521-0103 ; 0022-3565
ISSN (online)	1521-0103
ISSN	0022-3565
DOI	10.1124/jpet.124.002153
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uf I Zs.40: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Infection in neutropenic patients with cancer.

Bow, Eric J

Critical care clinics

2013 Volume 29, Issue 3, Page(s) 411–441

Abstract: Neutropenic fever sepsis syndromes are common among patients with cancer who are receiving intensive cytotoxic systemic therapy. Recognition of the syndromes and timely initial antibacterial therapy is critical for survival and treatment success. ... ...

Abstract	Neutropenic fever sepsis syndromes are common among patients with cancer who are receiving intensive cytotoxic systemic therapy. Recognition of the syndromes and timely initial antibacterial therapy is critical for survival and treatment success. Outcomes are linked to myeloid reconstitution and recovery from neutropenia, control of active comorbidities, and appropriate treatment of the infections that underlie the sepsis syndrome. Hematologists and oncologists must be clear about the prognosis and treatment goals to work effectively with critical care physicians toward the best outcomes for patients with cancer who develop neutropenic sepsis syndromes.
MeSH term(s)	APACHE ; Anti-Bacterial Agents/therapeutic use ; Antifungal Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Chemoprevention ; Comorbidity ; Cytotoxins/adverse effects ; Cytotoxins/therapeutic use ; Fever ; Hospital Mortality ; Humans ; Intensive Care Units/statistics & numerical data ; Multiple Organ Failure/etiology ; Multiple Organ Failure/mortality ; Neoplasms/complications ; Neoplasms/drug therapy ; Neoplasms/mortality ; Neutropenia/chemically induced ; Neutropenia/complications ; Neutropenia/microbiology ; Neutropenia/mortality ; Sepsis/drug therapy ; Sepsis/etiology ; Sepsis/mortality ; Syndrome
Chemical Substances	Anti-Bacterial Agents ; Antifungal Agents ; Antineoplastic Agents ; Cytotoxins
Language	English
Publishing date	2013-07
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1006423-0
ISSN	1557-8232 ; 0749-0704
ISSN (online)	1557-8232
ISSN	0749-0704
DOI	10.1016/j.ccc.2013.03.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 990: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies.

Young, Jo-Anne H / Andes, David R / Ardura, Monica I / Arrieta, Antonio / Bow, Eric J / Chandrasekar, Pranatharthi H / Chen, Sharon C A / Hammond, Sarah P / Husain, Shahid / Koo, Sophia / Lavergne, Valéry / Nguyen, M Hong / Patterson, Thomas F / So, Miranda / Thompson, George R / Morrissey, C Orla / Schuster, Mindy G

Open forum infectious diseases

2024 Volume 11, Issue 3, Page(s) ofae082

Abstract: The epidemiology of invasive aspergillosis (IA) is evolving. To define the patient groups who will most likely benefit from primary or ... ...

Abstract	The epidemiology of invasive aspergillosis (IA) is evolving. To define the patient groups who will most likely benefit from primary or secondary
Language	English
Publishing date	2024-02-06
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2757767-3
ISSN	2328-8957
ISSN	2328-8957
DOI	10.1093/ofid/ofae082
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Evaluation of the Impact of the Urgent Cancer Care Clinic on Emergency Department Visits, Primary Care Clinician Visits, and Hospitalizations in Winnipeg, Manitoba.

Galloway, Katie / Lambert, Pascal / Bow, Eric J / Czaykowski, Piotr / Fatoye, Tunji / Goldenberg, Benjamin / Kristjanson, Mark / Singh, Harminder / Bucher, Oliver / Decker, Kathleen

Current oncology (Toronto, Ont.)

2023 Volume 30, Issue 7, Page(s) 6771–6785

Abstract: The urgent cancer care (UCC) clinic at CancerCare Manitoba (CCMB) opened in 2013 to provide care to individuals diagnosed with cancer and serious blood disorders experiencing complications from the underlying disorder or its treatment. This study ... ...

Abstract	The urgent cancer care (UCC) clinic at CancerCare Manitoba (CCMB) opened in 2013 to provide care to individuals diagnosed with cancer and serious blood disorders experiencing complications from the underlying disorder or its treatment. This study examined the impact of the UCC clinic on other health care utilization in Winnipeg, Manitoba, Canada. An interrupted time series study design was used to compare the rates of emergency department (ED) visits, primary care clinician (PCC) visits, and hospitalizations from 1 January 2010 to 31 December 2015. Rates of ED visits were also stratified by ED location, severity, and cancer type. We found a 6% (95% CI 1.00-1.13,
MeSH term(s)	Humans ; Manitoba/epidemiology ; Quality of Life ; Hospitalization ; Emergency Service, Hospital ; Neoplasms/epidemiology ; Neoplasms/therapy ; Primary Health Care
Language	English
Publishing date	2023-07-18
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol30070496
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4305: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy.

Santos, Edna J / Nassehi, Nima / Bow, Eric W / Chambers, Dana R / Gutman, Eugene S / Jacobson, Arthur E / Lutz, Joshua A / Marsh, Samuel A / Rice, Kenner C / Sulima, Agnieszka / Selley, Dana E / Negus, S Stevens

Pharmacology research & perspectives

2023 Volume 11, Issue 4, Page(s) e01111

Abstract: Low-efficacy mu-opioid receptor (MOR) agonists represent promising therapeutics, but existing compounds (e.g., buprenorphine, nalbuphine) span a limited range of low MOR efficacies and have poor MOR selectivity. Accordingly, new and selective low- ... ...

Abstract	Low-efficacy mu-opioid receptor (MOR) agonists represent promising therapeutics, but existing compounds (e.g., buprenorphine, nalbuphine) span a limited range of low MOR efficacies and have poor MOR selectivity. Accordingly, new and selective low-efficacy MOR agonists are of interest. A novel set of chiral C9-substituted phenylmorphans has been reported to display improved MOR selectivity and a range of high-to-low MOR efficacies under other conditions; however, a full opioid receptor binding profile for these drugs has not been described. Additionally, studies in mice will be useful for preclinical characterization of these novel compounds, but the pharmacology of these drugs in mice has also not been examined. Accordingly, the present study characterized the binding selectivity and in vitro efficacy of these compounds using assays of opioid receptor binding and ligand-stimulated [
MeSH term(s)	Animals ; Female ; Male ; Mice ; Analgesics, Opioid/pharmacology ; Buprenorphine/pharmacology ; Guanosine 5'-O-(3-Thiotriphosphate) ; Ligands ; Receptors, Opioid, mu/agonists
Chemical Substances	Analgesics, Opioid ; Buprenorphine (40D3SCR4GZ) ; Guanosine 5'-O-(3-Thiotriphosphate) (37589-80-3) ; Ligands ; phenylmorphan (91190-14-6) ; tianeptine (0T493YFU8O) ; Receptors, Opioid, mu
Language	English
Publishing date	2023-06-28
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural
ZDB-ID	2740389-0
ISSN	2052-1707 ; 2052-1707
ISSN (online)	2052-1707
ISSN	2052-1707
DOI	10.1002/prp2.1111
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Point: fluoroquinolone-based antibacterial chemoprophylaxis in neutropenic cancer patients works for defined outcomes in defined populations, but must be used wisely.

Bow, Eric J

Journal of the National Comprehensive Cancer Network : JNCCN

2009 Volume 2, Issue 5, Page(s) 433–444

Abstract: Fluoroquinolone-based antibacterial chemoprophylaxis administered in situations in which the prevalence of fluoroquinolone-resistant Escherichia coli is low (< 3% to 5%) can reliably reduce the risk for invasive gram-negative bacillary infection, and, if ...

Abstract	Fluoroquinolone-based antibacterial chemoprophylaxis administered in situations in which the prevalence of fluoroquinolone-resistant Escherichia coli is low (< 3% to 5%) can reliably reduce the risk for invasive gram-negative bacillary infection, and, if supplemented by gram-positive agents such as rifampin, penicillin, or macrolides, can reduce the risk of developing invasive infections caused by gram-positive microorganisms, including Viridans streptococci and coagulase-negative staphylococci. In the published literature, fluoroquinolone-based chemoprophylaxis does not reliably reduce the incidence of febrile neutropenic episodes, neutropenic episode-related mortality, or physician-initiated systemic antimicrobial prescribing behavior. Prophylaxis should only be prescribed in defined patient populations from the first day of cytotoxic therapy until neutrophil regeneration in environments in which the prevalence of gram-negative bacillary resistance to the prophylaxis strategy is low. Small phase II clinical trials suggest that empirical antibacterial therapy of unexplained fevers in neutropenic patients receiving effective fluoroquinolone-based prophylaxis under defined epidemiologic circumstances may be safely discontinued early. Better discriminators of infection in febrile neutropenic patients are needed.
MeSH term(s)	Anti-Bacterial Agents/economics ; Anti-Bacterial Agents/therapeutic use ; Antibiotic Prophylaxis/economics ; Antibiotic Prophylaxis/methods ; Fluoroquinolones/economics ; Fluoroquinolones/therapeutic use ; Humans ; Meta-Analysis as Topic ; Neoplasms/complications ; Neoplasms/drug therapy ; Neoplasms/economics ; Neoplasms/mortality ; Neutropenia/complications ; Neutropenia/drug therapy ; Neutropenia/economics ; Neutropenia/mortality ; Population ; Treatment Outcome
Chemical Substances	Anti-Bacterial Agents ; Fluoroquinolones
Language	English
Publishing date	2009-09-03
Publishing country	United States
Document type	Evaluation Studies ; Journal Article ; Review
ZDB-ID	2250759-0
ISSN	1540-1405
ISSN	1540-1405
DOI	10.6004/jnccn.2004.0034
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6365: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Considerations in the approach to invasive fungal infection in patients with haematological malignancies.

Bow, Eric J

British journal of haematology

2008 Volume 140, Issue 2, Page(s) 133–152

Abstract: Invasive infections because of opportunistic yeasts and moulds have contributed significantly to the morbidity and mortality associated with potentially curative treatment for haematological malignancies. Many risk factors have been identified that ... ...

Abstract	Invasive infections because of opportunistic yeasts and moulds have contributed significantly to the morbidity and mortality associated with potentially curative treatment for haematological malignancies. Many risk factors have been identified that permit the clinician to predict the likelihood of these infections. The diagnostic process involves maintaining a high index of suspicion based upon an understanding of the clinical circumstances under which invasive fungal infections occur, of the spectrum of fungal syndromes, and of the advantages and limitations of diagnostic testing strategies now available. Treatment strategies may be categorized as prophylactic, pre-emptive, empiric, or directed based upon the circumstances. The therapeutic options have increased in recent years but are not applicable to all clinical circumstances. These considerations are discussed.
MeSH term(s)	Antifungal Agents/therapeutic use ; Hematologic Neoplasms/complications ; Humans ; Mycoses/complications ; Mycoses/diagnosis ; Mycoses/epidemiology ; Mycoses/therapy ; Opportunistic Infections/complications ; Opportunistic Infections/diagnosis ; Opportunistic Infections/epidemiology ; Opportunistic Infections/therapy ; Randomized Controlled Trials as Topic
Chemical Substances	Antifungal Agents
Language	English
Publishing date	2008-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	80077-6
ISSN	1365-2141 ; 0007-1048
ISSN (online)	1365-2141
ISSN	0007-1048
DOI	10.1111/j.1365-2141.2007.06906.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.182: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Of yeasts and hyphae: a hematologist's approach to antifungal therapy.

Bow, Eric J

Hematology. American Society of Hematology. Education Program

2006 , Page(s) 361–367

Abstract: Improvements in anticancer treatments, the ability to modify myelosuppression profiles, greater duration and intensity of immunosuppression, and the variety of available antimicrobial therapies have influenced the spectrum of pathogens associated with ... ...

Abstract	Improvements in anticancer treatments, the ability to modify myelosuppression profiles, greater duration and intensity of immunosuppression, and the variety of available antimicrobial therapies have influenced the spectrum of pathogens associated with invasive fungal infection complicating treatment of hematological malignancies and hematopoietic stem cell transplantation. The approaches to the management of these infections encompass strategies of prevention for all those at risk, preemptive therapy based upon surrogates of infection before the onset of clinical disease, empirical therapy for patients with clinical evidence of early disease, and directed or targeted therapy for infected patients with established disease. Chemoprophylaxis is effective if applied to the highest risk patients over the duration of the risk. Preemptive strategies, while promising, have yet to be validated and linked to reliably predictive non-microbiological diagnostic techniques. Empirical antifungal therapy, as it is currently applied, now seems questionable. Patients with probable or proven invasive fungal infection still have suboptimal outcomes despite the availability of promising anti-fungal agents. Strategies examining the concept of dose-intensity and combination regimens require careful study and cannot yet be regarded as an acceptable standard of practice.
MeSH term(s)	Antifungal Agents/therapeutic use ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/therapy ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Immunosuppression/adverse effects ; Mycoses/drug therapy ; Mycoses/etiology ; Mycoses/prevention & control ; Opportunistic Infections/drug therapy ; Opportunistic Infections/prevention & control
Chemical Substances	Antifungal Agents
Language	English
Publishing date	2006
Publishing country	United States
Document type	Journal Article ; Review
ISSN	1520-4391
ISSN	1520-4391
DOI	10.1182/asheducation-2006.1.361
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED